Clinical Gastroenterology and Hepatology
Volume 7, Issue 5 , Pages 600-602, May 2009

False-Positive Secretin Stimulation Test for Gastrinoma Associated With the Use of Proton Pump Inhibitor Therapy

  • Joshua A. Goldman

      Affiliations

    • Section of Gastroenterology, Boston University School of Medicine, Boston, Massachusetts
    • Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts
  • ,
  • Wanda P. Blanton

      Affiliations

    • Section of Gastroenterology, Boston University School of Medicine, Boston, Massachusetts
    • Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts
  • ,
  • David W. Hay

      Affiliations

    • Section of Gastroenterology, Boston University School of Medicine, Boston, Massachusetts
  • ,
  • M. Michael Wolfe

      Affiliations

    • Section of Gastroenterology, Boston University School of Medicine, Boston, Massachusetts
    • Section of Gastroenterology, Boston Medical Center, Boston, Massachusetts
    • Corresponding Author InformationReprint requests Address requests for reprints to: M. Michael Wolfe, MD, Section of Gastroenterology, Boston Medical Center, 650 Albany Street, Room 504, Boston, Massachusetts 02118. fax: (617) 638-7785

published online 25 February 2009.

We report the case of a 22-year-old woman who was referred for evaluation of possible Zollinger–Ellison syndrome because of hypergastrinemia and a positive secretin stimulation test. She was being treated with proton pump inhibitors (PPIs) for severe gastroesophageal reflux disease during her initial evaluation. At cessation of PPI therapy, her fasting serum gastrin levels normalized, as did her response to secretin injection. Previous reports describing false-positive secretin tests have been limited to cases of hypergastrinemia in the setting of chronic atrophic gastritis, presumably a result of achlorhydria. This case represents a clearly documented instance of PPI-related hypergastrinemia with a false-positive secretin test, with subsequent normalization of serum gastrin and a negative secretin test after withdrawal of PPI therapy. The current case emphasizes the need to assess the acid secretory status of individuals with hypergastrinemia and to discontinue the use of potent antisecretory agents, principally PPIs, to avoid the erroneous diagnosis of gastrinoma and before embarking on expensive and potentially invasive evaluations for the purpose of tumor localization.

Abbreviations used in this paper: PPI, proton pump inhibitor, ZES, Zollinger–Ellison syndrome

 

 Conflicts of interest The authors disclose no conflicts.

PII: S1542-3565(09)00142-6

doi:10.1016/j.cgh.2009.02.018

Clinical Gastroenterology and Hepatology
Volume 7, Issue 5 , Pages 600-602, May 2009